Xiao-Ding Liu

Xiao-Ding Liu

Auto-generated profile, based on publicly available information

Xiao-Ding Liu

Peking Union Medical College Hospital 1 Department of Pathology Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Nature
Verified
Journal Article
Closed access
PDF file
ABAlicia M. Braxton
Alicia M. Braxton
AKAshley L. Kiemen
Ashley L. Kiemen
MGMia P. Grahn
Mia P. Grahn
AFAndré Forjaz
André Forjaz
JPJeeun Parksong
Jeeun Parksong
LWLaura D. Wood
Laura D. Wood

10 October 2024 in EBioMedicine
Verified
Journal Article
Open access
ZZZhe Zhou
Zhe Zhou
DDDi Dong
Di Dong
YYYuyao Yuan
Yuyao Yuan
JLJuan Luo
Juan Luo
XLXiao-Ding Liu
Xiao-Ding Liu
YYYuxin Yin
Yuxin Yin
Background Metabolic reprogramming plays a pivotal role in cancer progression, contributing to substantial intratumour heterogeneity and influencing fl uencing tumour behaviour. However, a systematic characterization of metabolic heterogeneity across multiple cancer types at the single-cell level remains limited. Methods We integrated 296 tumour and normal samples spanning six common cancer types to construct a single-cell compendium of metabolic gene expression profiles fi les and identify cell type-specific fi c metabolic properties and reprogramming patterns. A computational approach based on non-negative matrix factorization (NMF) was utilised to identify metabolic meta-programs (MMPs) showing intratumour heterogeneity. In-vitro cell experiments were conducted to confirm fi rm the associations between MMPs and chemotherapy resistance, as well as the function of key metabolic regulators. Survival analyses were performed to assess clinical relevance of cellular metabolic properties. Findings Our analysis revealed shared glycolysis upregulation and divergent regulation of citric acid cycle across different cell types. In malignant cells, we identified fi ed a colorectal cancer-specific fi c MMP associated with resistance to the cuproptosis inducer elesclomol, validated through in-vitro cell experiments. Furthermore, our fi ndings enabled the stratification fi cation of patients into distinct prognostic subtypes based on metabolic properties of specific fi c cell types, such as myeloid cells. Interpretation This study presents a nuanced understanding of multilayered metabolic heterogeneity, offering valuable insights into potential personalized therapies targeting tumour metabolism. Funding National Key Research and Development Program of China (2021YFA1300601). National Natural Science Foundation of China (key grants 82030081 and 81874235). The Shenzhen High-level Hospital Construction Fund and Shenzhen Basic Research Key Project (JCYJ20220818102811024). The Lam Chung Nin Foundation for Systems Biomedicine.

1 January 2021 in Pathology - Research and Practice
Verified
Journal Article
Open access
XLXiao-Ding Liu
Xiao-Ding Liu
ZZZhi-Wen Zhang
Zhi-Wen Zhang
HWHuan-Wen Wu
Huan-Wen Wu
ZLZhiyong Liang
Zhiyong Liang
Mitogen-activated protein kinase kinase 4 (MAP2K4) is a tumor suppressor in many cancers. However, its roles and action mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unclear. Here, we analyzed MAP2K4 and its downstream kinases (c-Jun N-terminal kinase (JNK) and p38) using immunohistochemical staining and their prognostic significances using univariate and multivariate Cox proportional hazards regression analysis in our PDAC cohort. Then, we validated MAP2K4/JNK/p38 mRNA levels and prognostic significances using The Cancer Genome Atlas (TCGA) database. Finally, we evaluated the effects of MAP2K4 on the proliferation and invasion of PDAC cells. MAP2K4, JNK, and p38 proteins were expressed in 97.3 % (72/74), 95.6 % (65/68), and 88.6 % (62/70) of the samples, respectively, and their levels in tumor tissues were significantly higher than those in normal ducts. MAP2K4 protein expression was lower in male patients (p = 0.028). In our PDAC cohort, advanced TNM stage, low MAP2K4, and high JNK protein levels were significant prognostic factors for poor overall survival (OS) based on a univariate survival analysis (p = 0.006, p < 0.001, and p = 0.004, respectively). N stage and MAP2K4 and JNK protein levels were independent prognostic factors for OS based on multivariate analysis. We then built a prognosis prediction nomogram combining the standard TNM staging system with MAP2K4 and JNK expression that had a Harrell's C-index of 0.645. The new prognosis prediction model effectively stratified the resected patients with PDAC, from both our cohort and TCGA database, into low- and high-risk groups. Finally, MAP2K4 overexpression inhibited pancreatic cancer cell proliferation and migration in vitro. This study shows that reduced protein and mRNA levels of MAP2K4 found in PDAC patients, coupled to in vitro effects observed, support the tumor suppressor role of MAP2K4 in PDAC. Importantly, combining MAP2K4 and JNK expression with the TNM staging system results in a better prediction of postoperative survival of patients with PDAC.

2 October 2026
Verified
Other
Open access
XYXianglin Yin
Xianglin Yin
XLXiao-Ding Liu
Xiao-Ding Liu
LCLulu Cheng
Lulu Cheng
LYLin Yang
Lin Yang
YFYujie Fu
Yujie Fu
ZLZhiyong Liang
Zhiyong Liang
S5A. Sequencing information of m6A-seq (CON and ATRA groups);S5B. Sequencing information of m6A-seq (SC and A5-KD groups);S5C. Sequencing information of RIP-seq

2 October 2026
Verified
Other
Open access
XYXianglin Yin
Xianglin Yin
XLXiao-Ding Liu
Xiao-Ding Liu
LCLulu Cheng
Lulu Cheng
LYLin Yang
Lin Yang
YFYujie Fu
Yujie Fu
ZLZhiyong Liang
Zhiyong Liang
Table S1A. Basic clinicopathological information of fibroblast donors;Table S1B. Independent fibroblast lines used in each experiment;Table S1C. Basic clinicalpathological information of PDAC patients in the TMA cohort;Table S1D. Basic clinicopathological information of non-TMA PDAC cases

2 October 2026
Verified
Other
Open access
PDF file
XYXianglin Yin
Xianglin Yin
XLXiao-Ding Liu
Xiao-Ding Liu
LCLulu Cheng
Lulu Cheng
LYLin Yang
Lin Yang
YFYujie Fu
Yujie Fu
ZLZhiyong Liang
Zhiyong Liang
Extended functional validation of ALKBH5-mediated CAF–PCC crosstalk.